Similar articles for PMID: 18725374

Year	Number of Results
2001	1
2002	4
2003	3
2004	6
2005	4
2006	9
2007	9
2008	3
2009	8
2010	3
2011	7
2012	10
2013	8
2014	5
2015	4
2016	4
2017	3
2018	3
2019	1
2021	2
2022	1
2024	0

1

The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy.

Olivieri I, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, Cantini F, Cutro MS, Mathieu A, Matucci-Cerinic M, Pappone N, Punzi L, Scarpa R, Mantovani LG; PACE working group. Olivieri I, et al. Rheumatology (Oxford). 2008 Nov;47(11):1664-70. doi: 10.1093/rheumatology/ken320. Epub 2008 Aug 24. Rheumatology (Oxford). 2008. PMID: 18725374 Free PMC article.

2

The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.

Bravo Vergel Y, Hawkins NS, Claxton K, Asseburg C, Palmer S, Woolacott N, Bruce IN, Sculpher MJ. Bravo Vergel Y, et al. Rheumatology (Oxford). 2007 Nov;46(11):1729-35. doi: 10.1093/rheumatology/kem221. Rheumatology (Oxford). 2007. PMID: 17956918

3

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R. Woolacott N, et al. Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. doi: 10.3310/hta10310. Health Technol Assess. 2006. PMID: 16948890 Free article. Review.

4

Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis.

Cawson MR, Mitchell SA, Knight C, Wildey H, Spurden D, Bird A, Orme ME. Cawson MR, et al. BMC Musculoskelet Disord. 2014 Jan 20;15:26. doi: 10.1186/1471-2474-15-26. BMC Musculoskelet Disord. 2014. PMID: 24444034 Free PMC article. Review.

5

Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.

Bansback NJ, Ara R, Barkham N, Brennan A, Fraser AD, Conway P, Reynolds A, Emery P. Bansback NJ, et al. Rheumatology (Oxford). 2006 Aug;45(8):1029-38. doi: 10.1093/rheumatology/kel147. Epub 2006 Jun 16. Rheumatology (Oxford). 2006. PMID: 16782734

6

TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden.

Kobelt G, Eberhardt K, Geborek P. Kobelt G, et al. Ann Rheum Dis. 2004 Jan;63(1):4-10. doi: 10.1136/ard.2003.010629. Ann Rheum Dis. 2004. PMID: 14672883 Free PMC article.

7

Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study.

Olivieri I, Cortesi PA, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, Cantini F, Ciampichini R, Cutro MS, Mathieu A, Matucci-Cerinic M, Punzi L, Scarpa R, Mantovani LG; PACE Working Group. Olivieri I, et al. Clin Exp Rheumatol. 2016 Jan-Feb;34(1):68-75. Epub 2015 Dec 3. Clin Exp Rheumatol. 2016. PMID: 26633622 Clinical Trial.

8

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T. McLeod C, et al. Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. doi: 10.3310/hta11280. Health Technol Assess. 2007. PMID: 17651658 Free article. Review.

9

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A. Chen YF, et al. Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. doi: 10.3310/hta10420. Health Technol Assess. 2006. PMID: 17049139 Free article. Review.

10

Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.

Nguyen CM, Bounthavong M, Mendes MA, Christopher ML, Tran JN, Kazerooni R, Morreale AP. Nguyen CM, et al. Pharmacoeconomics. 2012 Jul 1;30(7):575-93. doi: 10.2165/11594990-000000000-00000. Pharmacoeconomics. 2012. PMID: 22640174 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

89 results

Results by year